JLPC(SH:600513) Ge Long Hui·2026-02-06 09:51Core Viewpoint - The company plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB to support its strategic development and enhance its core competitiveness [1] Group 1: Capital Increase Details - The registered capital of Lianhuan (Anqing) will increase from 131.52 million RMB to 181.52 million RMB following the capital increase [1] - The capital increase is aimed at meeting key funding needs for product research and development, license acquisition, and production line expansion [1] Group 2: Financial Stability and Impact - The company currently has a stable and good financial condition, and the capital increase will not adversely affect its normal operations or cash flow [1] - The use of self-owned and self-raised funds for the capital increase ensures that there will be no significant negative impact on the company's operating performance or shareholder interests [1]